Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

January 31, 2017- Interviewed by Steven E. Greer, MD Jerry S. Wolinsky, M.D.,

Neurologist at UTHealth,

This entry was posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas. Bookmark the permalink.

One Response to Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

  1. Jerry Wolinsky, MD says:

    Dear Steve,

    Thanks for all of your persistence in getting this done. Nice and very fast work!

    Best as always,

    Jerry S. Wolinsky, MD
    Emeritus Professor in Neurology

    McGovern Medical School
    part of UTHealth | The University of Texas Health Science Center at Houston
    Houston’s Health University

Leave a Reply

Your email address will not be published. Required fields are marked *